Bioassay Labor für biologische Analytik GmbH

Im Neuenheimer Feld 515
69120 Heidelberg
Germany

About Bioassay

Bioassay GmbH specializes in developing, validating and performing bioanalytical assays in Pharmacology and Toxicology, with particular expertise in potency, safety and other assays under GMP for biopharmaceuticals, including therapeutic antibodies, hormones and cytokines. Bioassay GmbH was privately founded in 2002; we are now a 20+ strong company headquartered in Heidelberg, serving clients in the biotechnology, chemistry and cosmetics sectors. In 2017, we extended our expertise to customized peptide syntheses and peptide-specific antibodies by merging with our Heidelberg Technology Park neighbors, PSL Peptide Specialty Laboratories GmbH (PSL).

Here you will find Bioassay Labor für biologische Analytik GmbH

Last viewed contents

Ariadne Genomics and Jubilant Biosys Announce Strategic Alliance - Providing Curated Metabolic, Signaling, and Disease Pathway Databases as an Add-on to Pathway Analysis Software

Go to page

Multiplicom receives €200,000 grant for novel non-invasive pre-natal test - IWT grant to support development of early aneuploidy detection during pregnancy

Go to page

AEterna Zentaris: First Patient Dosing for Safety Trial of Phase 3 Program with Cetrorelix in Benign Prostatic Hyperplasia

Go to page

Ori Biotech raises over $100 million in Series B funding - Innovative cell and gene therapy manufacturing platform

Go to page

TranScrip Partners appoints David Oxlade as Chairman of the Board

Go to page

Sequenom Announces Exclusive Licensing Agreement with Genomic Nanosystems for Digital PCR Technologies and Methods Patents

Go to page

Intercell announces first data from its Phase I clinical trial with vaccine candidate to prevent Clostridium difficile infections - Second part of the study in the target population of elderly subjects will be initiated

Go to page

Excellent early results in large OvPlex ovarian cancer biomarker study

Go to page

Silence Therapeutics to receive $1.9m Milestone Payment as Pfizer and Quark commence Phase II Trial

Go to page

Raptor Pharmaceuticals Expands Board of Directors and Scientific Advisory Board

Go to page

Amorfix A(4) Assay Provides New Insights Into Alzheimer's Disease Pre-clinical Development Mouse Models - Amorfix Quantifies Rate of Accumulation of Amyloid in Seven Mouse Models of AD

Go to page